Skip to main content

Table 5 Clinical parameters with dapagliflozin in increased LDL-C and decreased LDL-C subgroup

From: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

  Increased LDL-C group (n = 20) Decreased LDL-C group (n = 20) p valuesb p valuesc
Pre treatment Post treatment % change p valuesa Pre treatment Post treatment % change p valuesa
Age (years) 51.6 ± 8.2     56.9 ± 7.8     0.047*  
BW (kg) 78.8 ± 14.3 76.8 ± 15.4 −2.5 0.002* 78.0 ± 14.7 75.5 ± 14.5 −3.2 0.001* 0.853 0.394
AST (IU/L) 36.1 ± 22.3 29.4 ± 15.9 −18.6 <0.001* 32.7 ± 16.3 24.1 ± 7.7 −26.3 0.002* 0.596 0.622
ALT (IU/L) 52.5 ± 46.1 39.9 ± 31.9 −24.0 0.032* 40.4 ± 23.6 26.7 ± 11.7 −33.9 0.030* 0.312 0.874
γGTP (IU/L) 51.0 ± 40.5 50.3 ± 62.6 −1.4 0.930 55.5 ± 46.5 34.0 ± 20.4 −38.7 0.030* 0.750 0.119
BUN (mg/dL) 14.1 ± 3.8 16.3 ± 4.3 15.6 0.013* 15.1 ± 4.9 17.3 ± 5.8 14.6 0.010* 0.470 0.996
Cre (mg/dL) 0.71 ± 0.15 0.72 ± 0.17 1.4 0.700 0.72 ± 0.19 0.77 ± 0.29 6.9 0.170 0.964 0.258
eGFR (mL/min/1.73 m2) 89.0 ± 18.8 88.0 ± 17.6 −1.1 0.661 83.3 ± 18.1 81.7 ± 22.1 −1.9 0.507 0.342 0.861
FPG (mg/dL) 152 ± 46 127 ± 27 −16.4 0.006* 138 ± 50.1 116 ± 21 −15.9 0.040* 0.382 0.815
HbA1c (%) 7.51 ± 1.1 6.92 ± 0.94 −7.9 0.002* 7.72 ± 1.1 6.81 ± 0.67 −11.8 <0.001* 0.575 0.225
CPR index 2.77 ± 15.2 2.35 ± 1.28 −15.2 0.008* 2.82 ± 1.28 2.44 ± 1.82 −13.4 0.243 0.922 0.486
Adiponectin (ng/mL) 5.5 ± 3.8 7.2 ± 5.4 30.9 0.002* 6.5 ± 2.8 8.0 ± 2.6 23.1 0.001* 0.383 0.675
  1. Data are expressed as mean ± standard deviation or percent changes after the treatment. Clinical and laboratory parameters in the subgroup whose LDL-C was increased or decreased by dapagliflozin treatment were analyzed
  2. BW body weight, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyltranspeptidase, BUN blood urea nitrogen, Cre creatinine, FPG fasting plasma glucose, LDL-C low-density lipoprotein-cholesterol
  3. ap values for the intragroup comparison (pre vs. post treatment values in each subgroup, * p < 0.05)
  4. bp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the pre treatment values, * p < 0.05)
  5. cp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the changes from pre to post treatment, * p < 0.05)